Moderna Q3 FY2026: $1.31 billion revenue, $0.38 EPS, guidance raised
Moderna posted a $162 million GAAP profit in FY2026 Q3 on $1.313 billion of revenue and raised full-year growth guidance to 15.0%–25.0%. The catch is seasonality: nine-month revenue was $1.847 billion and the nine-month net loss $1.963 billion. Read this quarter as a seasonal peak plus cost cuts, not yet a new earnings base.
1 · Expected vs. Actual
Free preview belowDiluted GAAP EPS was $0.38 versus a loss of $0.51 a year ago and a consensus estimate of -$1.2755, an enormous beat in percentage terms. It came from revenue timing plus R&D falling 27.0% to $583 million, not from a permanently reset cost base. Year-to-date diluted EPS is still -$4.93.
Revenue was $1.313 billion, up 29.0% from $1.016 billion a year earlier, split $780 million U.S. and $533 million international. The driver was COVID vaccine deliveries under long-term government contracts abroad, not a broad-based uptick. Put it next to Q2 2026's $145 million to see how seasonal this business still is.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-06
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.